Exploring The Legal Architecture Of Human Experimentation In India: An Analytical Study
International Journal of Drug Delivery Technology · 11.05.2026 · 16 (26s)
DOI: 10.25258/ijddt.16.26s.129 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 11.05.2026. Verfasst von Dr. Atul Jain und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Human experimentation is a crucial component of biomedical advancement, but poses serious ethical and legal challenges, especially in developing countries like india. This analytical study explores the evolution, structure, and shortcomings of india's legal framework governing human experimentation. Anchored in international ethical norms such as the nuremberg code, the declaration of helsinki, and the cioms guidelines, india's regulatory system has evolved significantly over the past four decades. The paper critically examines key legal instruments such as the drugs and cosmetics act, 1940, the new drugs and clinical trials rules, 2019 (ndctr), and the role of the indian council of medical research (icmr) in setting ethical guidelines. It assesses the functioning of institutional ethics committees (iecs), the informed consent process, and the protection of vulnerable populations. Judicial interventions, especially in landmark cases like swasthya adhikar manch and the hpv vaccine pil, have played a transformative role in prompting regulatory reforms. Comparative analysis with institutional review boards (irbs) in the u.S. And research ethics committees (recs) in the u.K. Reveals that while india has made significant progress in aligning with global norms, implementation remains weak due to institutional inertia, limited oversight capacity, and socio-economic disparities. The paper concludes with a detailed critique of persistent challenges—such as fragmented regulation, inconsistent ethics committee functioning, therapeutic misconception, and weak compensation mechanisms—and offers concrete policy recommendations. These include enacting a unified bioethics law, establishing a national tribunal for trial-related grievances, and enhancing public accountability through better data transparency and institutional reform. India stands at a crossroads, requiring urgent legal consolidation and ethical recalibration to ensure that human dignity is upheld in all research endeavors.
Zitieren
APA
Jain, D. A., Golder, D. P., & Mishra, D. N. (2026). Exploring The Legal Architecture Of Human Experimentation In India: An Analytical Study. International Journal of Drug Delivery Technology, 16(26s). https://doi.org/10.25258/ijddt.16.26s.129
Vancouver
Jain DA, Golder DP, Mishra DN. Exploring The Legal Architecture Of Human Experimentation In India: An Analytical Study. International Journal of Drug Delivery Technology. 2026;16(26s). doi:10.25258/ijddt.16.26s.129
BibTeX
@article{Jain2026,
author = {Jain, Dr. Atul and Golder, Dr. Papiya and Mishra, Dr. Neha},
title = {Exploring The Legal Architecture Of Human Experimentation In India: An Analytical Study},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {26s},
doi = {10.25258/ijddt.16.26s.129}
}
EUVIMED